Re-evaluation of the Muscle-full Effect During Continuously Elevated Amino Acid Availability in Healthy Young Males

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-35
SponsorMaastricht University Medical Center

About this trial

Muscle tissue consists of proteins. These proteins are built up of a collection of smaller building blocks: amino acids. When protein is consumed, it gets digested and absorbed into the blood. The body can use these amino acids, by taking them up from thecirculation. By consuming sufficient protein through our diet, we ensure that the body is provided with enough amino acids to enable muscle protein building. Sufficient muscle protein synthesis is important for maintaining muscle function and strength.

Previous research has shown that when 20 to 25g of protein is eaten, muscle protein synthesis is maximized. It is therefore recommended to eat 20g of protein per meal. However, it is currently unclear what happens to muscle protein synthesis rates if multiple meals are eaten. When multiple meals are consumed, amino acids appear in the circulation for prolonged period of time.

Theoretically, when there are a high amino acid concentrations in the blood, muscle protein synthesis rates will increase. Contrary to this theory, a study more than 20 years ago showed otherwise. It was observed that muscle protein synthesis rates are only elevated for2 hours afterwhich they decrease again. This phenomenon was referred to as the "muscle-full" effect. Because this phenomenon is in contrast with more previous studies, the objective is to replicate that study. This is important so that nutritional advice for healthy, but also clinical populations in the future can be improved.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Male sex

Aged between 18 - 35 years

Healthy (assessed based on routine medical questionnaire)

BMI between 18.5 - 30 kg/m2

Disqualifiers

Smoking

Involved in progressive exercise training

A history of neuromuscular problems

Use of anticoagulants

Trial design

Design model

Single group

Treatments tested in this trial

  • Continuous intravenous stable isotope amino acid tracer infusion

    Other intervention

    During the single 12 h trial day, a primed continuous stable isotope infusion will run in order to assess muscle protein synthesis in the basal (4 h) and post-prandial (8 h) state.

  • Amino acid infusion

    Other intervention

    In order to assess muscle protein synthesis rates during continuous elevated plasma amino acid availability, the amino acid infusion solution Vamin®14 EF will be used. Vamin® 14EF contains 85g amino acids per liter and will be administered in the post-prandial period for 8 hours to ensure a constant rate of amino acid infusion over the full assessment period of the primary outcome measure.

Treatment groups

12 Participants
are divided into 1 treatment group
Group A: Continuous amino acid infusionExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Muscle protein synthesis during continuous elevated plasma amino acid avaialbility in healthy young males

The primary endpoint is muscle protein synthesis rates (in %/h) over the full assessment period (8 h) as determined with contemporary stable isotope tracer methodology combined with repeated blood and muscle sampling. Muscle protein synthesis are calculated using plasma as precursor pool and the tracer enrichment in the muscle (measured with UPLC and GC-IRMS).

Time frame
8 hours

Secondary outcomes

1

Basal muscle protein synthesis rates

Basal muscle protein synthesis rates (in %/h) will be assessed over a 3h period as determined with contemporary stable isotope tracer methodology combined with repeated blood and muscle sampling. Muscle protein synthesis are calculated using plasma as precursor pool and the tracer enrichment in the muscle biopsy (measured with UPLC and GC-IRMS).

Time frame
3 hours
2

Whole-body protein kinetics

Including total rate of appearance, exogenous rate of appearance, endogenous rate of appearance, rate of disappearance based (all expressed as μmol/kg/min) on tracer plasma amino acid concentrations over time (measured with UPLC)

Time frame
8 hours
3

Whole-body protein metabolism

synthesis, breakdown, oxidation, net balance (all expressed as μmol/kg/h). Based on amino acid concentrations in plasma and breath samples (measured with UPLC and GC-IRMS).

Time frame
8 hours

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: